Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee
for Medicinal Products for Human Use (CHMP), the scientific committee of
the European Medicines Agency (EMA), has adopted a positive opinion on
the company’s Marketing Authorisation Application (MAA) for the
once-daily, single tablet regimen Stribild ® for the treatment
of HIV-1 infection in adult patients who are antiretroviral-naïve or are
infected with HIV-1 without known mutations associated with resistance
to any of the three antiretroviral agents in Stribild.
Sign-up for European CHMP Adopts Positive Opinion for Stribild®, a Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen for the Treatment of HIV-1 Infection investment picks